The Rancho Cordova-based company says it's launching a new joint venture to create an immune cell bank.

Chris Xu has been the CEO of Cesca Therapeutics Inc. (NASDAQ:KOOL) since 2016. First, this article will compare CEO...

RANCHO CORDOVA, Calif. , Oct. 14, 2019 /PRNewswire/ -- Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, today ...

RANCHO CORDOVA, Calif. , Oct. 2, 2019 /PRNewswire/ -- Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, and ThermoGenesis, ...

RANCHO CORDOVA, Calif. , Sept. 3, 2019 /PRNewswire/ -- Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, today ...

RANCHO CORDOVA, Calif. , Sept. 9, 2019 /PRNewswire/ -- Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, and ...

Global economic headwinds make it imperative to find suitable investments at home.

RANCHO CORDOVA, Calif., Oct. 31, 2019 /PRNewswire/ -- Cesca Therapeutics Inc. (KOOL), a market leader in automated cell processing for regenerative medicine, today announced that the company will change its name to ThermoGenesis Holdings, Inc. ("ThermoGenesis") in order to better reflect its new strategic focus on becoming a key solution provider for cell manufacturing tools and services in the cell and gene therapy markets. In conjunction with the name change, the company will begin trading under the new Nasdaq ticker symbol, THMO, effective Friday, November 1, 2019. ThermoGenesis® has been a well-respected brand for automated cell separation and cryostorage technologies in the stem cell and cord blood industry for nearly three decades.

RANCHO CORDOVA, Calif. , Aug. 6, 2019 /PRNewswire/ -- Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, today ...

This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. ACADIA Pharmaceuticals (NASDAQ: ACAD ) shares ...

RANCHO CORDOVA, Calif. , Oct. 24, 2019 /PRNewswire/ -- Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, today ...

RANCHO CORDOVA, Calif. , July 23, 2019 /PRNewswire/ -- ThermoGenesis, a wholly owned subsidiary of Cesca Therapeutics (Nasdaq: KOOL) and a market leader in automated cellular processing, today announced ...

Accelerate Diagnostics (AXDX) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Top Ranked Momentum Stocks to Buy for October 9th

Revenue Grows by 115% and the Company Records Positive Adjusted EBITDA for the Second Quarter of 2019 Conference Call to be Held Today at 1:30 p.m. PDT/4:30 p.m. EDT RANCHO CORDOVA, Calif. , Aug. 13, 2019 ...

We highlight five small-cap ETFs and stocks that have outperformed in September. These could be excellent plays for investors should the same trends prevail.

RANCHO CORDOVA, Calif. , Sept. 25, 2019 /PRNewswire/ -- Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, and ...

RANCHO CORDOVA, Calif., June 26, 2019 /PRNewswire/ -- Cesca Therapeutics Inc. (KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, today announced that on June 25, 2019 the Company received notification from the Qualifications Department of The Nasdaq Stock Market ("Nasdaq") that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which concerns minimum bid price listing requirements.  The Company's shares will continue to be traded on The Nasdaq Stock Market under the Symbol KOOL. Cesca Therapeutics Inc. is a market leader in cell processing technologies and autologous cell therapies for regenerative medicine.

RANCHO CORDOVA, Calif., Oct. 22, 2019 /PRNewswire/ -- Cesca Therapeutics Inc. (KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, and ThermoGenesis, its wholly owned device subsidiary, today announced that the company has entered into a definitive joint venture agreement with HealthBanks Biotech (USA) Inc., one of the world's leading stem cell bank networks, to commercialize its proprietary cell processing platform, CAR-TXpress™, for use in immune cell banking as well as for cell-based contract development and manufacturing services (CMO/CDMO). The joint venture will be named ImmuneCyte Life Sciences Inc. ("ImmuneCyte") and is expected to officially launch during the fourth quarter of 2019. Under terms of the agreement, ImmuneCyte will initially be owned 80% by HealthBanks Biotech and 20% by Cesca.

Cesca Therapeutics Inc. (NASDAQ:KOOL) shareholders should be happy to see the share price up 13% in the last month...